Nymox Pharmaceutical to Be Suspended From Nasdaq, Move to OTC

Dow Jones

Jul 06, 2023

By Josh Beckerman

Nymox Pharmaceutical said its shares will be suspended from Nasdaq at the open of business on Friday and will move to the OTC market after they didn't regain the required $1 share price within a six-month extension period.

Shares were down 5.6% after hours to 23.5 cents.

Nymox received a Nasdaq deficiency letter in July 2022 that it was out of compliance with the $1 closing bid price requirement.

In December, the biotechnology company submitted an application for Nymozarfex in Denmark for treatment of benign prostatic hyperplasia. The company said Wednesday that it expects a submission in another jurisdiction in the near future.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

July 05, 2023 18:38 ET (22:38 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2349561855"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2349561855\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2349561855?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-07-06 06:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2349561855","market":"sg","top_or_hot":-1,"title":"Nymox Pharmaceutical to Be Suspended From Nasdaq, Move to OTC","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Nymox Pharmaceutical said its shares will be suspended from Nasdaq at the open of business on Friday and will move to the OTC market after they didn't regain the required $1 share price within a six-month extension period. \n</p>\n<p>\n  Shares were down 5.6% after hours to 23.5 cents. \n</p>\n<p>\n  Nymox received a Nasdaq deficiency letter in July 2022 that it was out of compliance with the $1 closing bid price requirement. \n</p>\n<p>\n  In December, the biotechnology company submitted an application for Nymozarfex in Denmark for treatment of benign prostatic hyperplasia. The company said Wednesday that it expects a submission in another jurisdiction in the near future. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 05, 2023 18:38 ET (22:38 GMT)\n</p>\n<p>\n  Copyright (c) 2023 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nymox Pharmaceutical to Be Suspended From Nasdaq, Move to OTC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNymox Pharmaceutical to Be Suspended From Nasdaq, Move to OTC\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2023-07-06 06:38</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Nymox Pharmaceutical said its shares will be suspended from Nasdaq at the open of business on Friday and will move to the OTC market after they didn't regain the required $1 share price within a six-month extension period. \n</p>\n<p>\n  Shares were down 5.6% after hours to 23.5 cents. \n</p>\n<p>\n  Nymox received a Nasdaq deficiency letter in July 2022 that it was out of compliance with the $1 closing bid price requirement. \n</p>\n<p>\n  In December, the biotechnology company submitted an application for Nymozarfex in Denmark for treatment of benign prostatic hyperplasia. The company said Wednesday that it expects a submission in another jurisdiction in the near future. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 05, 2023 18:38 ET (22:38 GMT)\n</p>\n<p>\n  Copyright (c) 2023 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2349561855","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2349561855","pubTimestamp":1688596680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Nymox Pharmaceutical said its shares will be suspended from Nasdaq at the open of business on Friday and will move to the OTC market after they didn't regain the required $1 share price within a six-month extension period.Shares were down 5.6% after hours to 23.5 cents.Nymox received a Nasdaq deficiency letter in July 2022 that it was out of compliance with the $1 closing bid price requirement.In December, the biotechnology company submitted an application for Nymozarfex in Denmark for treatment of benign prostatic hyperplasia. The company said Wednesday that it expects a submission in another jurisdiction in the near future.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NYMXF":"Nymox Pharmaceutical Corp."},"translate_title":"Nymox制药将被暂停在纳斯达克，转移到OTC","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NQmain":1,"NYMX":1,"NYMXF":1},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Nymox Pharmaceutical said its shares will be suspended from Nasdaq at the open of business on Friday and will move to the OTC market after they didn't regain the required $1 share price within a six-month extension period. \n\n\n  Shares were down 5.6% after hours to 23.5 cents. \n\n\n  Nymox received a Nasdaq deficiency letter in July 2022 that it was out of compliance with the $1 closing bid price requirement. \n\n\n  In December, the biotechnology company submitted an application for Nymozarfex in Denmark for treatment of benign prostatic hyperplasia. The company said Wednesday that it expects a submission in another jurisdiction in the near future. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 05, 2023 18:38 ET (22:38 GMT)\n\n\n  Copyright (c) 2023 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}